222 related articles for article (PubMed ID: 34534363)
21. Associations of Plasma BACE1 Level and BACE1 C786G Gene Polymorphism with Cognitive Functions in Patients with Type 2 Diabetes: A Cross- Sectional Study.
Tian S; Huang R; Guo D; Lin H; Wang J; An K; Wang S
Curr Alzheimer Res; 2020; 17(4):355-364. PubMed ID: 32442083
[TBL] [Abstract][Full Text] [Related]
22. BACE1 and Other Alzheimer's-Related Biomarkers in Cerebrospinal Fluid and Plasma Distinguish Alzheimer's Disease Patients from Cognitively-Impaired Neurosyphilis Patients.
Zhang M; Zhong X; Shi H; Vanmechelen E; De Vos A; Liu S; Chen B; Mai N; Peng Q; Chen X; Wu Z; Hou L; Zhou H; Ouyang C; Zhang W; Liang W; Dai C; Ning Y
J Alzheimers Dis; 2020; 77(1):313-322. PubMed ID: 32804135
[TBL] [Abstract][Full Text] [Related]
23. The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.
De Vos A; Struyfs H; Jacobs D; Fransen E; Klewansky T; De Roeck E; Robberecht C; Van Broeckhoven C; Duyckaerts C; Engelborghs S; Vanmechelen E
J Alzheimers Dis; 2016 Jul; 53(4):1523-38. PubMed ID: 27392859
[TBL] [Abstract][Full Text] [Related]
24. Gray matter atrophy patterns of mild cognitive impairment subtypes.
Zhang H; Sachdev PS; Wen W; Kochan NA; Crawford JD; Brodaty H; Slavin MJ; Reppermund S; Draper B; Zhu W; Kang K; Trollor JN
J Neurol Sci; 2012 Apr; 315(1-2):26-32. PubMed ID: 22280946
[TBL] [Abstract][Full Text] [Related]
25. Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment.
Dugger BN; Davis K; Malek-Ahmadi M; Hentz JG; Sandhu S; Beach TG; Adler CH; Caselli RJ; Johnson TA; Serrano GE; Shill HA; Belden C; Driver-Dunckley E; Caviness JN; Sue LI; Jacobson S; Powell J; Sabbagh MN
BMC Neurol; 2015 Aug; 15():146. PubMed ID: 26289075
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal Fluid BACE1 Activity and sAβPPβ as Biomarker Candidates of Alzheimer's Disease.
Alexopoulos P; Thierjung N; Grimmer T; Ortner M; Economou P; Assimakopoulos K; Gourzis P; Politis A; Perneczky R;
Dement Geriatr Cogn Disord; 2018; 45(3-4):152-161. PubMed ID: 29788013
[TBL] [Abstract][Full Text] [Related]
27. Conversion pattern and predictive factor of mild cognitive impairment in elderly Koreans.
Shim SM; Song J; Kim JH; Jeon JP
Arch Gerontol Geriatr; 2016; 64():146-50. PubMed ID: 26896864
[TBL] [Abstract][Full Text] [Related]
28. Bilateral Hippocampal Volume Mediated the Relationship Between Plasma BACE1 Concentration and Memory Function in the Early Stage of Alzheimer's Disease: A Cross-Sectional Study.
Yin W; Wan K; Zhu W; Zhou X; Tang Y; Zheng W; Cao J; Song Y; Zhao H; Zhu X; Sun Z
J Alzheimers Dis; 2023; 92(3):1001-1013. PubMed ID: 36847009
[TBL] [Abstract][Full Text] [Related]
29. Language Differences Among Individuals with Normal Cognition, Amnestic and Non-Amnestic MCI, and Alzheimer's Disease.
Liampas I; Folia V; Morfakidou R; Siokas V; Yannakoulia M; Sakka P; Scarmeas N; Hadjigeorgiou G; Dardiotis E; Kosmidis MH
Arch Clin Neuropsychol; 2023 May; 38(4):525-536. PubMed ID: 36244060
[TBL] [Abstract][Full Text] [Related]
30. Platelet Membrane β-Secretase Activity in Mild Cognitive Impairment and Conversion to Dementia: a Longitudinal Study.
McGuinness B; Fuchs M; Barrett SL; Passmore AP; Johnston JA
J Alzheimers Dis; 2016; 49(4):1095-103. PubMed ID: 26639974
[TBL] [Abstract][Full Text] [Related]
31. A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved.
Espinosa A; Alegret M; Valero S; Vinyes-Junqué G; Hernández I; Mauleón A; Rosende-Roca M; Ruiz A; López O; Tárraga L; Boada M
J Alzheimers Dis; 2013; 34(3):769-80. PubMed ID: 23271318
[TBL] [Abstract][Full Text] [Related]
32. Differential and subtype-specific neuroimaging abnormalities in amnestic and nonamnestic mild cognitive impairment: A systematic review and meta-analysis.
Yeung MK; Chau AK; Chiu JY; Shek JT; Leung JP; Wong TC
Ageing Res Rev; 2022 Sep; 80():101675. PubMed ID: 35724862
[TBL] [Abstract][Full Text] [Related]
33. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
34. Risk of progression to Alzheimer's disease for different neuropsychological Mild Cognitive Impairment subtypes: A hierarchical meta-analysis of longitudinal studies.
Oltra-Cucarella J; Ferrer-Cascales R; Alegret M; Gasparini R; Díaz-Ortiz LM; Ríos R; Martínez-Nogueras ÁL; Onandia I; Pérez-Vicente JA; Cabello-Rodríguez L; Sánchez-SanSegundo M
Psychol Aging; 2018 Nov; 33(7):1007-1021. PubMed ID: 30284855
[TBL] [Abstract][Full Text] [Related]
35. The validity of amnestic MCI and non-amnestic MCI at age 75 in the prediction of Alzheimer's dementia and vascular dementia.
Jungwirth S; Zehetmayer S; Hinterberger M; Tragl KH; Fischer P
Int Psychogeriatr; 2012 Jun; 24(6):959-66. PubMed ID: 22300486
[TBL] [Abstract][Full Text] [Related]
36. Association of diabetes with amnestic and nonamnestic mild cognitive impairment.
Roberts RO; Knopman DS; Geda YE; Cha RH; Pankratz VS; Baertlein L; Boeve BF; Tangalos EG; Ivnik RJ; Mielke MM; Petersen RC
Alzheimers Dement; 2014 Jan; 10(1):18-26. PubMed ID: 23562428
[TBL] [Abstract][Full Text] [Related]
37. Novel Plasma miRNAs as Biomarkers and Therapeutic Targets of Alzheimer's Disease at the Prodromal Stage.
He H; Liu A; Zhang W; Yang H; Zhang M; Xu H; Liu Y; Hong B; Yan F; Yue L; Wang J; Xiao S; Xie Z; Wang T
J Alzheimers Dis; 2021; 83(2):779-790. PubMed ID: 34366343
[TBL] [Abstract][Full Text] [Related]
38. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates.
Duara R; Loewenstein DA; Greig MT; Potter E; Barker W; Raj A; Schinka J; Borenstein A; Schoenberg M; Wu Y; Banko J; Potter H
Am J Geriatr Psychiatry; 2011 Nov; 19(11):951-60. PubMed ID: 21422909
[TBL] [Abstract][Full Text] [Related]
39. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease.
Wu G; Sankaranarayanan S; Wong J; Tugusheva K; Michener MS; Shi X; Cook JJ; Simon AJ; Savage MJ
J Neurosci Res; 2012 Dec; 90(12):2247-58. PubMed ID: 22987781
[TBL] [Abstract][Full Text] [Related]
40. Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years.
Darmanthé N; Tabatabaei-Jafari H; Cherbuin N;
J Alzheimers Dis; 2021; 82(3):951-964. PubMed ID: 34120902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
